AGA GUIDELINES Bundle (free trial)

Luminal and Fistulizing Crohn’s Disease - Moderate-Severe

AGA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512411

Contents of this Issue

Navigation

Page 4 of 13

5 Recommendations a Recommendation Statements Strength of Recommendation Certainty of Evidence 2B. In adult outpatients with moderate to severe CD who never responded to anti- TNFα (primary nonresponse), the AGA recommends the use of ustekinumab and suggests the use of vedolizumab over no treatment for the induction of remission. Strong Conditional Moderate Low 2C. In adult outpatients with moderate to severe CD who previously responded to infliximab (secondary nonresponse), the AGA recommends the use of adalimumab or ustekinumab and suggests the use of vedolizumab over no treatment for the induction of remission. Comment: If adalimumab was the first-line drug used there is indirect evidence to suggest the option of using infliximab as a second-line agent. Strong Conditional Moderate Low 3A. In adult outpatients with moderate to severe CD, the AGA suggests against the use of thiopurines over no treatment for achieving remission. Conditional Very Low 3B. In adult outpatients with quiescent moderate to severe CD (or patients in corticosteroid- induced remission), the AGA suggests the use of thiopurines over no treatment for the maintenance of remission. Conditional Low 3C. In adult outpatients with moderate to severe CD, the AGA suggests the use of subcutaneous or intramuscular methotrexate monotherapy over no treatment for the induction and maintenance of remission. Conditional Moderate 3D. In adult outpatients with moderate to severe CD, the AGA suggests against the use of oral methotrexate monotherapy over no treatment for the induction and maintenance of remission. Conditional Very low 4. In adult outpatients with moderate to severe CD, the AGA recommends the use of biologic drug monotherapy over thiopurine monotherapy for the induction of remission. Strong Moderate

Articles in this issue

Archives of this issue

view archives of AGA GUIDELINES Bundle (free trial) - Luminal and Fistulizing Crohn’s Disease - Moderate-Severe